Journal article

Practical experience with ticagrelor: an Australian and New Zealand perspective.

Scott A Harding, William J Van Gaal, Ryan Schrale, Athula Gunasekara, John Amerena, Christian J Mussap, Philip E Aylward

Curr Med Res Opin | Published : 2015


OBJECTIVE: Ticagrelor is recommended in local and international guidelines as first-line therapy in combination with aspirin in patients presenting with acute coronary syndromes (ACS). The purpose of this article is to provide practical guidance regarding the use of ticagrelor in this setting. METHODS AND RESULTS: Ticagrelor, a direct-acting, reversible P2Y12 receptor antagonist, has a faster onset, and a more potent and predictable antiplatelet effect compared with clopidogrel. The authors recommend considering the use of ticagrelor in moderate-to-high risk ACS patients treated with an invasive approach and those managed non-invasively who have elevated troponin levels. Consistent with outc..

View full abstract

University of Melbourne Researchers